Cargando…
Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution
The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymer...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232123/ https://www.ncbi.nlm.nih.gov/pubmed/22139150 http://dx.doi.org/10.1107/S1744309111040267 |
_version_ | 1782218327502880768 |
---|---|
author | Patschull, Anathe O. M. Segu, Lakshmi Nyon, Mun Peak Lomas, David A. Nobeli, Irene Barrett, Tracey E. Gooptu, Bibek |
author_facet | Patschull, Anathe O. M. Segu, Lakshmi Nyon, Mun Peak Lomas, David A. Nobeli, Irene Barrett, Tracey E. Gooptu, Bibek |
author_sort | Patschull, Anathe O. M. |
collection | PubMed |
description | The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function. |
format | Online Article Text |
id | pubmed-3232123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Union of Crystallography |
record_format | MEDLINE/PubMed |
spelling | pubmed-32321232011-12-12 Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution Patschull, Anathe O. M. Segu, Lakshmi Nyon, Mun Peak Lomas, David A. Nobeli, Irene Barrett, Tracey E. Gooptu, Bibek Acta Crystallogr Sect F Struct Biol Cryst Commun Structural Communications The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function. International Union of Crystallography 2011-11-25 /pmc/articles/PMC3232123/ /pubmed/22139150 http://dx.doi.org/10.1107/S1744309111040267 Text en © Patschull et al. 2011 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited. |
spellingShingle | Structural Communications Patschull, Anathe O. M. Segu, Lakshmi Nyon, Mun Peak Lomas, David A. Nobeli, Irene Barrett, Tracey E. Gooptu, Bibek Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title | Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title_full | Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title_fullStr | Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title_full_unstemmed | Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title_short | Therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
title_sort | therapeutic target-site variability in α(1)-antitrypsin characterized at high resolution |
topic | Structural Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232123/ https://www.ncbi.nlm.nih.gov/pubmed/22139150 http://dx.doi.org/10.1107/S1744309111040267 |
work_keys_str_mv | AT patschullanatheom therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT segulakshmi therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT nyonmunpeak therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT lomasdavida therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT nobeliirene therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT barretttraceye therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution AT gooptubibek therapeutictargetsitevariabilityina1antitrypsincharacterizedathighresolution |